High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age.
Authors:
- T PhilipTPT Philip
- J L BernardJBJ L Bernard
- J M ZuckerJZJ M Zucker
- R PinkertonRPR Pinkerton
- P LutzPLP Lutz
- P BordigoniPBP Bordigoni
- E PlouvierEPE Plouvier
- A RobertARA Robert
- R CartonRCR Carton
- N PhilippeNPN Philippe
- 1 February 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (2) , 266-271
Abstract
Since January 1983, 56 consecutive children over 1 year of age with stage IV neuroblastoma entered an aggressive protocol, including chemotherapy, radiation therapy, and bone marrow transplantation. The induction protocol included platinum and epipodophyllotoxin (VM-26), alternating with cyclophosphamide, Adriamycin (Adria Laboratories, Columbus, OH), and vincristine (PE/CADO). Surgery was performed after 2 to 4 months, and consolidation with intensive chemoradiotherapy and bone marrow transplantation (BMT) was performed within 12 months of diagnosis. The combination of vincristine, melphalan and total body irradiation (TBI) was used before BMT, and no further treatment was administered before progression. With the exception of two allografts, autologous BMT (ABMT) was given in all cases and was purged using an immunomagnetic procedure (Kemshead technique) in 32 of 35 cases, and a chemical procedure in three of 35. Of the 56 patients, 45 were evaluable. Of those, 23 were grafted in partial remission (PR), and 14 were grafted in either complete remission (CR) or very good partial remission (VGPR). The acute toxic death rate was 19%, the relapse rate was 32%, and the progressive disease rate was 19%. The progression-free survival in the CR/VGPR group (ie, 44% at 32 months post-diagnosis) and in the PR group (13% at 32 months) was not significantly different (P greater than .05). At 24 months, the overall survival of the 56 unselected patients was 39% compared with 12% for comparable patients previously treated by our group (P less than .005).Keywords
This publication has 10 references indexed in Scilit:
- Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non‐Hodgkin's lymphomaBritish Journal of Haematology, 1985
- The radiobiology of human neuroblastomaRadiotherapy and Oncology, 1985
- Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalanBritish Journal of Haematology, 1984
- Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.Journal of Clinical Oncology, 1984
- Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution.Journal of Clinical Oncology, 1984
- REMOVAL OF NEUROBLASTOMA CELLS FROM BONE MARROW WITH MONOCLONAL ANTIBODIES CONJUGATED TO MAGNETIC MICROSPHERESThe Lancet, 1984
- Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies.Journal of Clinical Pathology, 1983
- High-dose melphalan with autologous marrow for treatment of advanced neuroblastomaBritish Journal of Cancer, 1982
- SELECTIVE TOXICITY OF 6-HYDROXYDOPAMINE AND ASCORBATE FOR HUMAN NEURO-BLASTOMA INVITRO - A MODEL FOR CLEARING MARROW PRIOR TO AUTOLOGOUS TRANSPLANT1982
- AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOID-LEUKEMIA IN RELAPSE OR IN COMPLETE REMISSION1982